Edgerton SM - Search Results

1

Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.

Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Gari HH, et al. Among authors: edgerton sm. Oncotarget. 2016 Mar 29;7(13):15757-71. doi: 10.18632/oncotarget.7462. Oncotarget. 2016. PMID: 26909599 Free PMC article.

2

Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, et al. Thor AD, et al. Among authors: edgerton sm. J Natl Cancer Inst. 1992 Jun 3;84(11):845-55. doi: 10.1093/jnci/84.11.845. J Natl Cancer Inst. 1992. PMID: 1317462

3

pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival.

Thor AD, Koerner FC, Edgerton SM, Wood WC, Stracher MA, Schwartz LH. Thor AD, et al. Among authors: edgerton sm. Breast Cancer Res Treat. 1992;21(2):111-9. doi: 10.1007/BF01836957. Breast Cancer Res Treat. 1992. PMID: 1627814

4

Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.

Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET. Louis DN, et al. Acta Neuropathol. 1991;81(6):675-9. doi: 10.1007/BF00296379. Acta Neuropathol. 1991. PMID: 1679278

5

pS2 expression and response to hormonal therapy in patients with advanced breast cancer.

Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD. Schwartz LH, et al. Among authors: edgerton sm. Cancer Res. 1991 Jan 15;51(2):624-8. Cancer Res. 1991. PMID: 1985778

6

Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit.

Lloveras B, Edgerton S, Thor AD. Lloveras B, et al. Am J Clin Pathol. 1991 Jan;95(1):41-7. doi: 10.1093/ajcp/95.1.41. Am J Clin Pathol. 1991. PMID: 1987751

7

Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations.

Thor A, Benz C, Moore D 2nd, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA. Thor A, et al. J Natl Cancer Inst. 1991 Feb 6;83(3):170-8. doi: 10.1093/jnci/83.3.170. J Natl Cancer Inst. 1991. PMID: 1988702

8

Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.

Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, et al. Thor AD, et al. Among authors: edgerton sm. Cancer Res. 1989 Dec 15;49(24 Pt 1):7147-52. Cancer Res. 1989. PMID: 2573426

9

Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications.

Thor AD, Edgerton SM. Thor AD, et al. Among authors: edgerton sm. Semin Nucl Med. 1989 Oct;19(4):295-308. doi: 10.1016/s0001-2998(89)80022-4. Semin Nucl Med. 1989. PMID: 2678481 Review.

10

Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma.

Axelsson K, Ljung BM, Moore DH 2nd, Thor AD, Chew KL, Edgerton SM, Smith HS, Mayall BH. Axelsson K, et al. Among authors: edgerton sm. J Natl Cancer Inst. 1995 Jul 5;87(13):997-1008. doi: 10.1093/jnci/87.13.997. J Natl Cancer Inst. 1995. PMID: 7543156

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

76 results

Search Page

Filters